Login to Your Account

Other News To Note

Wednesday, May 8, 2013
• Intas Biopharmaceuticals Ltd., of Ahmedabad, India, launched Mabtas in India. The product is a biosimilar version of Rituximab (Roche AG and Biogen Idec Inc.) indicated in the treatment of diseases characterized by excessive numbers of B cells, overactive B cells or dysfunctional B cells, such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription